Ignyta (NASDAQ: RXDX) has recently received a number of price target changes and ratings updates:

  • 10/18/2017 – Ignyta was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. “
  • 10/18/2017 – Ignyta had its price target raised by analysts at Ladenburg Thalmann Financial Services from $20.25 to $31.00.
  • 10/17/2017 – Ignyta was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Entrectinib has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), for NTRK fusion-positive solid tumors, primarily based on STARTRK-2 results.””
  • 10/12/2017 – Ignyta was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. “
  • 10/12/2017 – Ignyta had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $20.00 price target on the stock, up previously from $18.00.
  • 9/27/2017 – Ignyta had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock. They wrote, “RXDX completed enrollment in both NTRK and ROS1 arms, with interim data to be presented at IASLC on October 18th, and expects to have duration of response data, with the possibility of all patient data centrally reviewed, and top-line data for ROS1 and NTRK in early 2018.””
  • 9/6/2017 – Ignyta had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.

Ignyta, Inc. (NASDAQ:RXDX) opened at 15.60 on Tuesday. The stock’s 50 day moving average price is $12.81 and its 200-day moving average price is $9.83. Ignyta, Inc. has a 52 week low of $4.15 and a 52 week high of $18.30. The company’s market capitalization is $877.55 million.

Ignyta (NASDAQ:RXDX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.07. On average, equities research analysts predict that Ignyta, Inc. will post ($2.57) earnings per share for the current fiscal year.

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Receive News & Ratings for Ignyta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc and related companies with MarketBeat.com's FREE daily email newsletter.